몰큘린 바이오테크(MBRX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.61 (+7.16%), 시가총액 $0.01B, 52주 범위 $0.27 ~ $7.71.
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and W
몰큘린 바이오테크의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
몰큘린 바이오테크의 현재 주가는 $0.61 (+7.16%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
몰큘린 바이오테크의 시가총액은 약 $0.01B입니다.
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annam